Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies

Symptomatic benefit of momelotinib in patients with myelofibrosis: results from the SIMPLIFY phase III studies

<p><strong>Background:</strong>&nbsp;Myelofibrosis (MF)-associated constitutional symptoms can severely impact health-related quality of life. Clinical trials in MF traditionally measure symptom response to treatment as a landmark endpoint of total symptom score (TSS) reduction...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Mesa, RA, Hudgens, S, Floden, L, Harrison, CN, Palmer, J, Gupta, V, McLornan, DP, McMullin, MF, Kiladjian, J-J, Foltz, L, Platzbecker, U, Fox, ML, Mead, AJ, Ross, DM, Oh, ST, Perkins, A, Leahy, MF, Deheshi, S, Donahue, R, Klencke, BJ, Verstovsek, S
التنسيق: Journal article
اللغة:English
منشور في: Wiley 2023

مواد مشابهة